We sat down with Kathy Oubre, chief operating officer at the Pontchartrain Cancer Center, to discuss what practices have had to forgo during the coronavirus disease 2019 (COVID-19) crisis and how biosimilar access has been affected.
During 7 months of combatting the coronavirus disease 2019 (COVID-19) pandemic, US health care practices, especially in oncology, had to completely modify how they could safely treat patients. They may have reduced waiting room capacity, barred caregivers from attending appointments with patients, increased telehealth usage, or reworked priorities and postponed decisions.
Some health care experts believe the pandemic will improve the overall uptake of biosimilars because it has made cost savings more important. Many patients face financial hardships as a result of the crisis.
We sat down with Kathy Oubre, chief operating officer at the Pontchartrain Cancer Center in Louisiana, president of the Louisiana Medical Group Management Association, and a member of the board of directors for the Community Oncology Alliance, to discuss what practices had to do without during the COVID-19 crisis and how biosimilar access has been affected.
To learn more about COVID-19’s impact on biosimilars, check out our ebook here.
Escaping the Void: All Things Biosimilars With Craig & G
May 4th 2025To close out the Festival of Biologics, Craig Burton and Giuseppe Randazzo from the Association for Accessible Medicines and the Biosimilars Council tackle the current biosimilar landscape and how the industry can emerge from the "biosimilar void."
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Biosimilars Policy Roundup for March 2023—Podcast Edition
April 2nd 2023On this episode of Not So Different, we discuss some of the global biosimilar policy news that came out during the month of March, including a new bill in Congress and 2 Canadian jurisdictions implementing switching policies.
Biosimilars Gastroenterology Roundup for February 2023—Podcast Edition
March 5th 2023On this episode of Not So Different, we chronicle the latest gastroenterology news from February, including several updates on adalimumab and infliximab biosimilars and industry analyses on the utilization of these drugs and patient confidence in gastroenterologists’ recommendations.